Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305414 | 0.87 | APOBEC3G (0.37) | KMT2AMEN1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL3679104 | 0.83 | MAPT (0.41) | KMT2AMEN1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL4318105 | 0.83 | MAPT (0.39) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4317065 | 0.80 | MAPT (0.50) | KMT2AMEN1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL4308119 | 0.79 | KMT2A (0.36) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL4312071 | 0.76 | MEN1 (0.51) | KMT2AMEN1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL4213603 | 0.75 | CFTR (0.43) | KMT2AMEN1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL4318080 | 0.74 | SLC2A1 (0.35) | KMT2AMEN1MAPTPOLBALDH1A1 | |
| SCHEMBL3847767 | 0.74 | KMT2A (0.41) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21266883 | 0.73 | FFAR1 (0.38) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962830-B1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7605266-B2 | Azaindole inhibitors of Aurora kinases | SMITHKLINE BEECHAM (US) | 2009-10-20 | — | — | US | disclosed |
| US-7495102-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | GLAXOSMITHKLINE LLC | 2008-12-11 | — | — | US | disclosed |
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | SMITHKLINE BEECHAM CORPORATION | 2008-10-02 | — | — | US | disclosed |
| EP-1962830-A2 | AZAINDOLE INHIBITORS OF AURORA KINASES | SmithKline Beecham Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7419988-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORP (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-7282588-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM (US) | 2007-10-16 | — | — | US | disclosed |
| WO-2007076348-A2 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | KMT2A 105/4885MEN1 946/4885MAPT 2145/4885 |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | KMT2A 105/4885MEN1 946/4885MAPT 2145/4885 |
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | AURKA, AURKC, PLK1 | KMT2A 1323/4885MEN1 931/4885MAPT 649/4885 |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | KMT2A 105/4885MEN1 946/4885MAPT 2145/4885 |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | AURKA, AURKC, AURKB | KMT2A 113/4885MEN1 400/4885MAPT 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.